New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4541-4549

  Palladini, Giovanni ^a,b   Dispenzieri, Angela ^c   Gertz, Morie A ^c   Kumar, Shaji ^c   Wechalekar, Ashutosh ^d   Hawkins, Philip N ^d   Schönland, Stefan ^e   Hegenbart, Ute ^e   Comenzo, Raymond ^f   Kastritis, Efstathios ^g   Dimopoulos, Meletios A ^g   Jaccard, Arnaud ^h   Klersy, Catherine ^a   Merlini, Giampaolo ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c MAYO CLINIC   (United States)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f TUFTS MEDICAL CENTER   (United States)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; BIOLOGICAL MARKER; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; NUCLEOSIDE DERIVATIVE; PREDNISONE; THALIDOMIDE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; COHORT ANALYSIS; ECHOCARDIOGRAPHY; EUROPEAN UNION; FEMALE; HEART FUNCTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELIABILITY; SURVIVAL; TREATMENT RESPONSE; UNITED STATES; VALIDATION STUDY;

AGED; AMYLOIDOSIS; BIOLOGICAL MARKERS; COHORT STUDIES; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS;

EID: 84871772553     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.7614     Document Type: Article

References (27)

1. Merlini G, Stone M: Dangerous small B-cell clones. Blood 108:2520-2530, 2006
2. Abraham RS, Katzmann JA, Clark RJ, et al: Quantitative analysis of serum free light chains: A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119:274-278, 2003
3. Bochtler T, Hegenbart U, Heiss C, et al: Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 93:459-462, 2008
4. Palladini G, Russo P, Bosoni T, et al: Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55:499-504, 2009
5. Kumar S, Dispenzieri A, Katzmann JA, et al: Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features. Blood 116:5126-5129, 2010
6. Dispenzieri A, Kyle R, Gertz M, et al: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361:1787-1789, 2003
7. Palladini G, Campana C, Klersy C, et al: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440-2445, 2003
8. Dispenzieri A, Gertz MA, Kyle RA, et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757, 2004
9. Kristen AV, Giannitsis E, Lehrke S, et al: Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 116:2455-2461, 2010
10. Palladini G, Barassi A, Klersy C, et al: The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116:3426-3430, 2010
11. Dietrich S, Schönland SO, Benner A, et al: Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 116:522-528, 2010
12. Lachmann HJ, Gallimore R, Gillmore JD, et al: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122:78-84, 2003
13. Sanchorawala V, Seldin DC, Magnani B, et al: Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 36:597-600, 2005
14. Dispenzieri A, Lacy MQ, Katzmann JA, et al: Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107:3378-3383, 2006
15. Palladini G, Lavatelli F, Russo P, et al: Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854-3858, 2006
16. Gertz MA, Comenzo R, Falk RH, et al: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319-328, 2005
17. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
18. Melzi d'Eril G, Tagnochetti T, Nauti A, et al: Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem 49:1554-1555, 2003
19. Wu A, Smith A, Wieczorek S, et al: Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92:628-631, 2003
20. Gertz M, Lacy M, Dispenzieri A, et al: Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 92:1415-1418, 2007
21. Paiva B, Vídriales MB, Pérez JJ, et al: The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in AL amyloidosis. Blood 117:3613-3616, 2011
22. Dispenzieri A, Zhang L, Katzmann JA, et al: Appraisal of immunoglobulin free light chain as a marker of response. Blood 111:4908-4915, 2008
23. Kumar SK, Dispenzieri A, Lacy MQ, et al: Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 86:251-255, 2011
24. Mair J: Biochemistry of B-type natriuretic peptide: Where are we now? Clin Chem Lab Med 46:1507-1514, 2008
25. Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2012 (in press)
26. Gibbs SDJ, Sattianayagam PT, Whelan CJ, et al: Rise in Serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: Implications for organ response assessement. Amyloid 17:179, 2010 (suppl 1; abstr P-170)
27. Dispenzieri A, Dingli D, Kumar SK, et al: Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 85:757-759, 2010